Chief Commercial Officer · AGIOS PHARMACEUTICALS, INC. (AGIO)

Tsveta Milanova

FY2023 is the first fiscal year CompBrief holds for Tsveta Milanova as a named executive officer of AGIOS PHARMACEUTICALS; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$3,733,273

Salary $507,875Stock awards $699,978Bonus $150,000

1st of 5 named executive officers at Agios Pharmaceuticals by FY2023 total.

5 named officers on file for AGIOS PHARMACEUTICALS, FY2023

Tsveta Milanova’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 2 equity grants, each cited to its filing
  • AGIO’s disclosed peer group of 14 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how AGIOS PHARMACEUTICALS’s whole pay program stands against its peers

  • AGIOS PHARMACEUTICALS’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on AGIO→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 26, 2024 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Tsveta Milanova’s full pay file as a PDF — free

More than this page: up to 10 years of Tsveta’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Tsveta Milanova compensation by year

AGIOS PHARMACEUTICALS Summary Compensation Table · the one fiscal year held
In US dollars, as AGIOS PHARMACEUTICALS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2023
Salary$507,875
Bonus$150,000
Stock awards$699,978
Option awards$2,094,247
Non-equity incentive$266,220
Pension and deferred compensation$0
All other$14,953
Total$3,733,273

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: AGIOS PHARMACEUTICALS, INC. DEF 14A filed April 26, 2024, accession 0001193125-24-117951, and prior-year filings. Open the filing on EDGAR.

How this page was built: the AGIOS PHARMACEUTICALS, INC. filed document, accession 0001193125-24-117951. Every figure is read from that document and cited to the page and table it appears in. Filed April 26, 2024.

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
RSU25,426$566,237—
Option135,682—$27.53

Per the Outstanding Equity Awards at Fiscal Year-End table in AGIOS PHARMACEUTICALS, INC.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

30 Form 4 lines since the FY2023 proxy (filed April 26, 2024)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-06-18Grant or award derivative—3,000$0.003,000
2026-06-18Exercise or conversion derivative—3,000$0.009,000
2026-04-02Sale10b5-13,262$34.7146,829
2026-04-02Exercise or conversion10b5-18,500$0.0050,091
2026-04-02Exercise or conversion derivative10b5-18,500$0.008,500
2026-03-02Exercise or conversion10b5-14,000$0.0042,778
2026-03-02Exercise or conversion derivative10b5-15,666$0.005,667
2026-03-02Exercise or conversion10b5-15,666$0.0040,459

The 8 most recent of 30 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

AGIOS PHARMACEUTICALS’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Tsveta Milanova · this pageChief Commercial Officer$3,733,273
Brian GoffChief Executive Officer$3,416,453
Sarah GheuensChief Medical Officer, Head of Research & Development$2,870,159
James BurnsChief Legal Officer$1,934,540
Cecilia JonesChief Financial Officer$1,208,784

The full AGIOS PHARMACEUTICALS compensation record

free company brief

This page is one person within AGIOS PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are AGIOS PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Tsveta Milanova's compensation dossier · One-time report. No refunds.